How to Reverse Prediabetes, According to an MD

What "Reversing" Prediabetes Actually Means

Reversing prediabetes means returning blood glucose markers to the normal range and keeping them there. Specifically, that means an A1C below 5.7 percent, a fasting plasma glucose below 100 mg/dL, or a two-hour oral glucose tolerance test result below 140 mg/dL, sustained for at least 12 months without pharmacologic support if the reversal was achieved through lifestyle alone.

The American Diabetes Association 2024 Standards of Care define prediabetes as fasting glucose 100 to 125 mg/dL, A1C 5.7 to 6.4 percent, or a two-hour glucose value of 140 to 199 mg/dL on a 75-gram oral glucose tolerance test (ADA Standards of Care, 2024). Crossing back below those thresholds is achievable. It is not automatic.

Why the Word "Reversal" Is Accurate Here

Some clinicians prefer "remission" because beta-cell dysfunction may persist at a subclinical level even after glucose normalizes. The practical difference is small for most patients. What matters clinically is that normalized markers reduce cardiovascular risk, slow microvascular changes, and delay or eliminate the need for diabetes medications. A 2022 analysis in the BMJ confirmed that individuals who achieved glucose normalization from prediabetes had cardiovascular event rates similar to those who were never dysglycemic.

Who Has the Best Odds

Reversal is more likely in people who are within the first three years of a prediabetes diagnosis, who have an A1C closer to 5.7 than to 6.4 percent, who have meaningful weight to lose, and who do not yet have significant beta-cell dysfunction. Age under 60 and absence of first-degree family history of type 2 diabetes also predict better outcomes, though the interventions below benefit all groups.

The Diabetes Prevention Program: What the Evidence Actually Shows

The DPP trial is the single most important piece of evidence for prediabetes reversal. Knowing its numbers lets you set realistic, accurate goals rather than vague ones.

Trial Design and Core Results

The DPP enrolled 3,234 adults with impaired fasting glucose or impaired glucose tolerance and randomized them to intensive lifestyle intervention, metformin 850 mg twice daily, or placebo (Knowler et al., NEJM 2002). Mean follow-up was 2.8 years.

The lifestyle arm achieved a 58 percent relative risk reduction in progression to type 2 diabetes compared with placebo. Metformin reduced risk by 31 percent. The lifestyle benefit was larger in participants over age 60, where risk reduction reached 71 percent. Weight loss in the lifestyle arm averaged 5.6 kg at one year.

The DPP Outcomes Study: Long-Term Follow-Up

The DPP Outcomes Study followed participants for an additional 15 years. At the 15-year mark, cumulative incidence of diabetes remained lower in the lifestyle group than in the placebo group, though the difference narrowed over time as lifestyle adherence declined (Knowler et al., Lancet Diabetes Endocrinology 2009). The key takeaway: sustained behavioral change, not a short course of effort, drives durable results.

Translating DPP Targets to Real Life

The DPP lifestyle goal was explicit: lose 7 percent of body weight and exercise 150 minutes per week. For a 200-pound person, 7 percent means 14 pounds. That is a concrete number to give a patient. The program used 16 sessions with a lifestyle coach in the first six months, then monthly contact. The structure mattered as much as the targets.

Diet: Which Eating Patterns Move the Markers

No single diet works for every person with prediabetes, but several dietary patterns have direct evidence linking them to improved fasting glucose and A1C.

Mediterranean Diet

A 2020 meta-analysis in Nutrients (NCBI) covering 29 randomized trials found that Mediterranean diet adherence reduced fasting glucose by an average of 3.89 mg/dL and A1C by 0.30 percentage points in people with dysglycemia or metabolic syndrome. The pattern emphasizes olive oil, legumes, fish, vegetables, and whole grains while limiting refined carbohydrates and red meat.

Low-Glycemic-Index Eating

Replacing high-glycemic foods (white bread, white rice, sugary beverages) with low-glycemic alternatives (legumes, non-starchy vegetables, intact whole grains) reduces postprandial glucose spikes. A Cochrane review (Cochrane Library, 2019) found that low-GI diets reduced A1C by 0.20 percentage points and fasting glucose by 0.57 mmol/L versus high-GI controls in people with type 1 or type 2 diabetes. The effect in prediabetes is directionally consistent.

What to Cut First

Sugary beverages are the highest-yield single target. Each daily serving of sugar-sweetened beverages is associated with a 26 percent higher relative risk of type 2 diabetes in prospective cohort data (Malik et al., Diabetes Care, 2010, PubMed). Cutting soda, juice, and sweetened coffee drinks before making any other change is a defensible first step for most patients.

Caloric Deficit and Weight Loss Primacy

Dietary pattern matters, but total weight loss may matter more than the specific diet used to achieve it. The DPP did not mandate a specific diet. It targeted a caloric deficit sufficient to achieve 7 percent weight loss. A 500-calorie daily deficit produces roughly 1 pound per week of loss, which is a realistic and sustainable rate for most people.

Exercise: The Dose That Moves Glucose

Physical activity lowers blood glucose through two mechanisms: acute glucose uptake into skeletal muscle via insulin-independent GLUT4 translocation, and chronic improvement in insulin sensitivity through increased mitochondrial density and reduced visceral adiposity.

Aerobic Exercise

The ADA 2024 Standards of Care recommend at least 150 minutes per week of moderate-intensity aerobic activity for adults with prediabetes or diabetes (ADA Standards of Care 2024). Moderate intensity means brisk walking, cycling, swimming, or anything that raises heart rate to 50 to 70 percent of maximum. Breaking 150 minutes into five 30-minute sessions works as well as longer, less frequent sessions.

Resistance Training

Adding two to three resistance training sessions per week amplifies the glucose-lowering effect beyond what aerobic exercise alone produces. A meta-analysis in Diabetes Care (PubMed) found that combined aerobic and resistance training reduced A1C by 0.46 percentage points more than aerobic training alone in adults with type 2 diabetes. The effect in prediabetes is likely similar given the shared mechanism.

Post-Meal Walking

Ten minutes of walking after each meal reduces two-hour postprandial glucose more effectively than a single 30-minute walk at another time of day, according to a 2013 trial published in Diabetes Care (PubMed). This is a practical, low-barrier recommendation for sedentary patients who find carving out 30-minute blocks difficult.

Sleep and Stress: The Variables Most Clinicians Underemphasize

Poor sleep and chronic psychological stress both drive cortisol elevation and sympathetic nervous system activation, which raise fasting glucose through hepatic gluconeogenesis. These are modifiable targets, not background noise.

Sleep Duration and Quality

Adults sleeping fewer than six hours per night have significantly higher risk of impaired glucose tolerance. A study in Diabetologia (PubMed) found that short sleep duration was associated with a 28 percent higher prevalence of type 2 diabetes after adjustment for obesity, physical activity, and diet. For prediabetes reversal, targeting seven to nine hours of sleep is a clinical recommendation, not optional self-care.

Stress Reduction

Cortisol stimulates hepatic glucose output and suppresses insulin secretion. Mindfulness-based stress reduction (MBSR) programs running eight weeks in length have shown reductions in fasting glucose of 4 to 7 mg/dL in small randomized trials. The effect size is modest compared to diet and exercise but is additive. Patients dealing with high chronic stress may find glucose markers that are resistant to dietary change until stress management is addressed.

Medications for Prediabetes: When to Use Them

Lifestyle change is first-line. Medications are appropriate for specific patients, not everyone with prediabetes.

Metformin

The ADA 2024 Standards of Care recommend considering metformin for adults with prediabetes who are under age 60, have a BMI of 35 or above, or have a history of gestational diabetes, given its 31 percent risk reduction in the DPP trial (Knowler et al., NEJM 2002). The typical starting dose is 500 mg once daily with dinner, titrated to 850 mg twice daily over four weeks to reduce gastrointestinal side effects. Metformin is generic, inexpensive, and has a 60-year safety record.

The ADA's 2024 guideline states directly: "Metformin therapy for prevention of type 2 diabetes should be considered in those with prediabetes, especially those with BMI <35 kg/m2, age <60 years, or prior gestational diabetes mellitus."

GLP-1 Receptor Agonists

Semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) are not FDA-approved specifically for prediabetes, but their weight-loss effects produce meaningful glucose improvement. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg weekly produced 14.9 percent mean weight loss at 68 weeks versus 2.4 percent on placebo (Wilding et al., NEJM 2021). A large proportion of STEP-1 participants with baseline prediabetes converted to normoglycemia by week 68. GLP-1 agents may be appropriate for patients who have prediabetes and a BMI above 27 with a weight-related comorbidity, using the existing obesity indication as the prescribing rationale.

Acarbose

Acarbose 100 mg three times daily reduced diabetes progression by 25 percent in the STOP-NIDDM trial (N=1,429) by slowing intestinal carbohydrate absorption (Chiasson et al., Lancet 2002, PubMed). It is rarely used as a first choice in the U.S. Due to gastrointestinal side effects (flatulence in up to 74 percent of users) but remains an option for patients who cannot tolerate metformin.

Monitoring: How to Track Whether the Reversal Is Working

Without measurement, there is no feedback loop. Tracking the right markers at the right intervals is part of the clinical plan.

A1C and Fasting Glucose

The ADA recommends A1C testing every six to twelve months for people with prediabetes (ADA Standards of Care 2024). A1C reflects average glucose over the prior 90 days. Fasting plasma glucose, drawn after at least eight hours without caloric intake, gives a direct snapshot. Both should be tracked together because A1C can miss certain patterns of glucose dysregulation that fasting glucose catches.

Continuous Glucose Monitoring in Prediabetes

CGM devices such as the Dexterity Libre 3 or Dexterity G7 are not standard of care for prediabetes, but they offer real-time feedback on how specific foods, meals, and exercise sessions affect postprandial glucose. A 2023 study in Diabetes Care (PubMed) found that CGM-guided dietary changes in adults with prediabetes produced greater reductions in postprandial glucose variability than standard dietary advice alone. For motivated patients, a 90-day CGM trial while adjusting diet is a reasonable option.

Weight as a Proxy

Because weight loss drives much of the glucose improvement, tracking body weight weekly gives a leading indicator of whether the intervention is working before the next A1C draw. Patients who achieve and maintain 5 percent weight loss almost always see A1C move in the right direction.

A Clinical Decision Framework for Prediabetes Reversal

The following framework reflects standard clinical practice organized into a tiered decision process. It is not a substitute for individualized medical advice.

Tier 1 (all patients with prediabetes):

• Set a weight loss target of 5 to 7 percent of current body weight.
• Prescribe 150 minutes per week of moderate aerobic activity.
• Recommend eliminating sugary beverages entirely.
• Address sleep and schedule A1C recheck in six months.

Tier 2 (A1C 6.0 to 6.4% or BMI above 30):

• Add metformin 500 mg daily, titrate to 850 mg twice daily over four weeks.
• Refer to a structured DPP-recognized program (CDC-recognized programs are covered by Medicare and many private insurers).
• Consider dietitian referral for individualized meal planning.

Tier 3 (A1C approaching 6.4% or weight loss <3% after six months on Tier 1 and 2):

• Evaluate for GLP-1 receptor agonist therapy using obesity indication if BMI is 27 or above with a comorbidity.
• Repeat oral glucose tolerance test to confirm prediabetes status versus early type 2 diabetes.
• Increase monitoring to A1C every three months until stabilized.

How Long Does Reversal Take?

Most patients who respond to lifestyle intervention see meaningful A1C reduction within three to six months. The DPP lifestyle arm achieved its primary result at 2.8 years of follow-up, but individual participants showed glucose improvements as early as six months in. Weight loss of 5 percent or more, achievable in three to four months with consistent effort, typically moves fasting glucose by 5 to 10 mg/dL.

Patients who achieve normoglycemia should not assume the risk is eliminated permanently. The DPP Outcomes Study showed that 10-year cumulative diabetes incidence in the lifestyle arm was 37.8 percent versus 49.9 percent in the placebo arm, meaning that a substantial minority of people who normalized glucose eventually progressed to diabetes, often when lifestyle habits slipped (Diabetes Prevention Program Research Group, Lancet 2009, PubMed). Ongoing monitoring every six to twelve months is permanent, not time-limited.

Special Populations

Gestational Diabetes History

Women with a history of gestational diabetes mellitus (GDM) have a 50 percent lifetime risk of developing type 2 diabetes, according to ACOG Practice Bulletin No. 190. Postpartum screening with a 75-gram OGTT at six to twelve weeks postpartum is standard. For women who screen positive for prediabetes postpartum, all of the same lifestyle interventions apply, with the added urgency of a high baseline risk trajectory.

Older Adults

The DPP showed that the lifestyle intervention was most effective in adults over age 60, with 71 percent risk reduction versus 49 percent in those aged 25 to 44. Older adults may need exercise modifications (water aerobics, resistance bands, chair-based exercise) but should not be counseled that age limits their response.

Polycystic Ovary Syndrome

Women with PCOS have insulin resistance driven partly by androgen excess, making prediabetes common in this group. A 2017 systematic review in Human Reproduction Update (PubMed) found that metformin improved insulin sensitivity and reduced free androgen index in women with PCOS, supporting its use in this population for both glucose and hormonal outcomes.